Percheron Therapeutics released its earnings results on Aug 29, 2024. The company reported -$0.005 earnings per share for the quarter, missing the consensus estimate of -$0.004 by -$0.001.

Q: Is Percheron Therapeutics overvalued?

According to Wall Street analysts Percheron Therapeutics’s price is currently same. Get more investment ideas with TipRanks Premium

Q: What is Percheron Therapeutics’s EPS estimate?

Percheron Therapeutics’s EPS estimate is >-0.01.

13 Followers

PERCF Stock Chart & Stats

Advanced Chart >

Day’s Range― - ―

52-Week Range<$0.01 - $0.15

Previous CloseN/A

Volume44.70K

Average Volume (3M)2.82K

Market Cap

$5.39M

Enterprise Value$39.35M

Total Cash (Recent Filing)$1.90M

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.63

Next Earnings

Feb 26, 2025

EPS Estimate

>-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding1,087,437,600

10 Day Avg. Volume0

30 Day Avg. Volume2,823

Standard Deviation0.57

R-Squared0.02

Alpha0.05

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)112.18

Price to Cash Flow (P/CF)N/A

P/FCF Ratio0.00

Enterprise Value/Market Cap7.31

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$0.08

Price Target Upside0.00%

Rating ConsensusModerate Buy

Number of Analyst Covering2

Percheron Therapeutics News

PremiumCompany Announcements

Powerhouse Ventures Increases Stake in Percheron Therapeutics

3d ago

PremiumCompany Announcements

Change in Substantial Holding for Percheron Therapeutics

13d ago

PremiumCompany Announcements

Percheron Therapeutics Faces Boardroom Shakeup Amid Shareholder Requisition

13d ago

PremiumCompany Announcements

Powerhouse Ventures Acquires Substantial Stake in Percheron Therapeutics

14d ago

PremiumCompany Announcements

Percheron Therapeutics Director Boosts Shareholding

20d ago

PremiumCompany Announcements

Percheron Therapeutics Announces Cessation of Securities

1M ago

PremiumCompany Announcements

Percheron Therapeutics: Shareholding Increase Sparks Investor Interest

1M ago

PremiumCompany Announcements

Percheron Therapeutics Halts Avicursen Trial Amid Disappointing Results

1M ago

See More PERCF News >

Financials

Annual

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

0.50% Insiders

― Mutual Funds

― Other Institutional Investors

99.50% Public Companies and

Individual Investors

Detailed Ownership Overview >

PERCF FAQ

What was Percheron Therapeutics’s price range in the past 12 months?

Percheron Therapeutics lowest stock price was <$0.01 and its highest was $0.15 in the past 12 months.

What is Percheron Therapeutics’s market cap?

Percheron Therapeutics’s market cap is $5.39M.

When is Percheron Therapeutics’s upcoming earnings report date?

Percheron Therapeutics’s upcoming earnings report date is Feb 26, 2025 which is in 38 days.

How were Percheron Therapeutics’s earnings last quarter?

Percheron Therapeutics released its earnings results on Aug 29, 2024. The company reported -$0.005 earnings per share for the quarter, missing the consensus estimate of -$0.004 by -$0.001.

Is Percheron Therapeutics overvalued?

According to Wall Street analysts Percheron Therapeutics’s price is currently same. Get more investment ideas with TipRanks Premium

Does Percheron Therapeutics pay dividends?

Percheron Therapeutics does not currently pay dividends.

What is Percheron Therapeutics’s EPS estimate?

Percheron Therapeutics’s EPS estimate is >-0.01.

How many shares outstanding does Percheron Therapeutics have?

Percheron Therapeutics has 1,087,437,600 shares outstanding.

What happened to Percheron Therapeutics’s price movement after its last earnings report?

Percheron Therapeutics reported an EPS of -$0.005 in its last earnings report, missing expectations of -$0.004. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Percheron Therapeutics?

Currently, no hedge funds are holding shares in PERCF

---

Percheron Therapeutics Stock Smart Score

Unlock Smart Score

Fundamentals

Return on Equity

-121.27%

Trailing 12-Months

Asset Growth

13.51%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Percheron Therapeutics

Antisense Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. It operates through the ATL1102, and ATL1103 segments. The ATL1102 segment represents the second generation antisense inhibitor of CD49d, the alpha subunit of very late antigen-four. The ATL1103 segment refers to atesidorsen is an antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin. The company was founded in November 13, 2000 and is headquartered in Toorak, Australia.

---

PERCF Stock 12 Month Forecast

Average Price Target

$0.08

▲(0.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","-1":"-$1","-0.5":"-$0.5","0.5":"$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.1548000075,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$0.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.08,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$0.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.0061920003,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\"><$0.01</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2022","6":"Dec<br/>2023","9":"May<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.05,0.05806153903846154,0.06612307807692308,0.07418461711538463,0.08224615615384616,0.09030769519230769,0.09836923423076924,0.10643077326923078,0.11449231230769231,0.12255385134615386,0.1306153903846154,0.1386769294230769,0.14673846846153848,{"y":0.1548000075,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.05,0.05230769230769231,0.05461538461538462,0.05692307692307692,0.05923076923076923,0.06153846153846154,0.06384615384615384,0.06615384615384615,0.06846153846153846,0.07076923076923078,0.07307692307692308,0.07538461538461538,0.0776923076923077,{"y":0.08,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.05,0.04663015386923077,0.04326030773846154,0.03989046160769231,0.03652061547692308,0.03315076934615385,0.029780923215384617,0.026411077084615386,0.023041230953846154,0.019671384823076923,0.016301538692307695,0.012931692561538463,0.009561846430769232,{"y":0.0061920003,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.16,"date":1627776000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.19,"date":1635724800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.14,"date":1640995200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.1,"date":1648771200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.08,"date":1661990400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.04,"date":1688169600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.05,"date":1701388800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.01,"date":1704067200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.01,"date":1711929600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.01,"date":1714521600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.01,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.05,"date":1727740800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.05,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Technical Analysis

Similar Stocks

CSL

―

CHEOF

Cochlear Limited

―

RMD

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

―

NNCSF

Nanosonics Limited

―

CKDXF

Opthea Limited

―

Compare PERCF Stocks >

Best Analysts Covering PERCF

1 Year

Melissa BensonWilsons

1 Year Success Rate

2/4 ratings generated profit

1 Year Average Return

+14.27%

reiterated a buy rating 2 months ago

Copying Melissa Benson's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +14.27% per trade.

Best Analyst Covering >

Popular Stocks

---

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Percheron Therapeutics (PERCF) Stock Price & Analysis

PERCF Stock Chart & Stats

Percheron Therapeutics News

Financials

Options Prices

Ownership Overview

PERCF FAQ

Percheron Therapeutics Stock Smart Score

Analyst Consensus

Blogger Sentiment

Insider Transactions

News Sentiment

Technicals

Fundamentals

Company Description

Percheron Therapeutics

PERCF Stock 12 Month Forecast

Average Price Target

Technical Analysis

Best Analysts Covering PERCF

Become an Expert with TipRanks Premium